Administration, Intravesical

"Administration, Intravesical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.

Descriptor ID	D000283
MeSH Number(s)	E02.319.267.120.505
Concept/Terms	Administration, Intravesical Administration, Intravesical Intravesical Drug Administration Drug Administration, Bladder Administration, Intravesical Drug Administrations, Intravesical Drug Drug Administration, Intravesical Drug Administrations, Intravesical Intravesical Drug Administrations Intravesical Administration Administrations, Intravesical Intravesical Administrations Bladder Drug Administration Administration, Bladder Drug Administrations, Bladder Drug Bladder Drug Administrations Drug Administrations, Bladder Instillation, Bladder Instillation, Bladder Bladder Instillation Bladder Instillations Instillations, Bladder Intravesical Instillation Instillation, Intravesical Instillations, Intravesical Intravesical Instillations Intravesical Injection Intravesical Injection Injections, Intravesical Injection, Intravesical Intravesical Injections

Below are MeSH descriptors whose meaning is more general than "Administration, Intravesical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Drug Administration Routes [E02.319.267]
Administration, Topical [E02.319.267.120]
Administration, Intravesical [E02.319.267.120.505]

Below are MeSH descriptors whose meaning is related to "Administration, Intravesical".

Below are MeSH descriptors whose meaning is more specific than "Administration, Intravesical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Administration, Intravesical" by people in this website by year, and whether "Administration, Intravesical" was a major or minor topic of these publications.

Bar chart showing 88 publications over 25 distinct years, with a maximum of 9 publications in 2018

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
1995	2	2
1999	1	1
2000	2	2
2001	2	2
2002	1	1
2003	1	1
2004	1	1
2005	2	2
2006	3	3
2007	3	3
2008	5	5
2009	3	3
2010	1	1
2011	1	1
2012	5	5
2013	7	7
2014	1	1
2015	7	7
2016	8	8
2017	4	4
2018	9	9
2019	2	2
2020	8	8
2021	7	7
2022	2	2

Below are the most recent publications written about "Administration, Intravesical" by people in Profiles.

Lobo N, Martini A, Kamat AM. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2022 04; 22(4):361-370.

View in: PubMed
Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, Furuya H. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomark. 2022; 33(1):151-157.

View in: PubMed
Roumiguié M, Kamat AM, Bivalacqua TJ, Lerner SP, Kassouf W, Böhle A, Brausi M, Buckley R, Persad R, Colombel M, Lamm D, Palou-Redorta J, Soloway M, Brothers K, Steinberg G, Lotan Y, Sylvester R, Alfred Witjes J, Black PC. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 Jul; 82(1):34-46.

View in: PubMed
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Ylä-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

View in: PubMed
Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG. Urol Oncol. 2022 01; 40(1):9.e1-9.e7.

View in: PubMed
Bree KK, Brooks NA, Kamat AM. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer. Hematol Oncol Clin North Am. 2021 06; 35(3):513-529.

View in: PubMed
Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 03 01; 31(2):160-169.

View in: PubMed
Li R, Lerner SP, Kamat AM. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.

View in: PubMed
Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. Adv Ther. 2021 03; 38(3):1584-1600.

View in: PubMed
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.

View in: PubMed

People

Explore

Similar Concepts

Top Journals